Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

– First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients – New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS, May 9, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in…